crownbio.comPreclinical Oncology CRO | Contract Research Drug Development Company - CrownBio

img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081ev=PageView noscript=1" English 简体 繁體中文 日本語 General Contact About Company Mission & Vision What We Do Leadership Team About JSR Life Sciences Scientific Advisors Strategic Partners Careers News CVMD Menu Column 1 Cardiovascular Disease NHP Models Rodent Models Diabetes NHP Models Rodent Models Obesity NHP Models Rodent Models Menu Column 2 NAFLD/NASH NHP Models MS-NASH (FATZO) Liver Fibrosis Rodent Models Renal Disease NHP Models Rodent Models Menu Column 3 Safety/Toxicology Bioanalysis Clinical Chemistry and Biomarkers In Vivo PK/PD Non-GLP Toxicology Safety Pharmacology Biomarker Assay Services Cytokine and Chemokine Profiling Flow Cytometry Genomics Services Histology and Digital Pathology Rare Cell Analysis Oncology Menu Column 1 In Vivo Services Breast Cancer Preclinical Models Cell Line Derived Xenograft Models Cell Line and Model Authentication Custom Tumor Model Development Immuno-Oncology Models MuScreen Orthotopic and Bioluminescent Models Patient-Derived Xenograft Models (HuPrime/HuKemia) Prostate Cancer Preclinical Models Radiation Therapy Syngeneic Tumor Models Menu Column 2 In Vitro Services Cell Based Screening CrownSyn Cell Line and Model Authentication Cell Line Panels Flow Cytometry Platform Immuno-Oncology OmniScreen Cell Based Screening Service PDX-Derived Cell Lines Organoids Cell Line and Model Authentication Organoid and Immune Cell Co-Culture Ex Vivo Services 3D Assays Tumor Microarrays Menu Column 3 Immuno-Oncology CAR-T Cell Therapy Models Humanized Models Hematopoietic Stem Cell (HSC)-PDX MiXeno Human Target Knock-In Models HuGEMM HuCELL Murine Immunity Models and Services Tumor Homograft Models Syngeneic Tumor Models MuScreen Biomarker Discovery and CDx Biomarkers of Response (HuMark) Mouse Clinical Trials (HuTrial) Signatures of Response (HuSignature) Menu Column 4 Biomarker Assay Services Cytokine and Chemokine Profiling Flow Cytometry Genomics Services Histology and Digital Pathology Rare Cell Analysis Bioinformatics CrownSyn Pharmacology and Bioanalytical Services DMPK Services NHP Immuno-Safety Structural Biology Target Validation Oncology Databases HuBase OrganoidBase MuBase Onco Express XenoBase Inflammation Menu Column 1 In Vivo Models Inflammatory Bowel Disease (IBD) Rheumatoid Arthritis (RA) Menu Column 2 Biomarker Assay Services Cytokine and Chemokine Profiling Flow Cytometry Genomics Services Histology and Digital Pathology Rare Cell Analysis Models Cell Line Derived Xenograft HSC and PBMC Humanized Human Target Knock-In ( HuGEMM TM ) Patient-Derived Xenograft ( HuPrime TM ) Syngeneic Tumor Homograft ( MuPrime TM ) Resources Posters Publications Presentations White Papers On-Demand Webinars Events Quick Facts FactSheets Application Notes Blog Databases Onco Express HuBase OrganoidBase XenoBase MuBase Search Site Search 360 Call Email About Company Mission & Vision What We Do Leadership Team About JSR Life Sciences Scientific Advisors Strategic Partners News CVMD Cardiovascular Disease NHP Models Rodent Models Diabetes NHP Models Rodent Models Obesity NHP Models Rodent Models NAFLD/NASH NHP Models MS-NASH (FATZO) Liver Fibrosis Rodent Models Renal Disease NHP Models Rodent Models Safety/Toxicology Bioanalysis Clinical Chemistry and Biomarkers In Vivo PK/PD Non-GLP Toxicology Safety Pharmacology Oncology In Vivo Services Breast Cancer Preclinical Models Cell Line Derived Xenograft Models Cell Line and Model Authentication Custom Tumor Model Development Immuno-Oncology Models MuScreen Orthotopic and Bioluminescent Models Patient-Derived Xenograft Models Prostate Cancer Preclinical Models Radiation Therapy Syngeneic Tumor Models In Vitro Services Cell Based Screening CrownSyn Cell Line and Model Authentication Cell Line Panels Flow Cytometry Platform Immuno-Oncology OmniScreen Cell Based Screening Service PDX Derived Cell Lines Organoids Cell Line and Model Authentication Organoid and Immune Cell Co-Culture Ex Vivo Services 3D Assays Tumor Microarrays Immuno-Oncology CAR-T Cell Therapy Models Humanized Models Hematopoietic stem cell (HSC)-PDX HuGEMM HuCELL MiXeno Murine Immunity Models and Services Tumor Homograft Models Syngeneic Tumor Models MuScreen Biomarker Discovery and CDx Biomarkers of Response (HuMark) Mouse Clinical Trials (HuTrial) Signatures of Response (HuSignature) Biomarker Assay Services Cytokine and Chemokine Profiling Flow Cytometry Genomics Services Histology and Digital Pathology Rare Cell Analysis Bioinformatics CrownSyn Pharmacology and Bioanalytical Services DMPK Services NHP Immuno-Safety Structural Biology Target Validation Oncology Databases HuBase OrganoidBase MuBase Onco Express XenoBase Inflammation In Vivo Models Inflammatory Bowel Disease Rheumatoid Arthritis (RA) Biomarker Servicers Cytokine and Chemokine Profiling Flow Cytometry Platform Genomics Services Histology and Digital Pathology Platform Rare Cell Analysis Models Cell Line Derived Xenograft HSC and PBMC Humanized Human Target Knock-In ( HuGEMM TM ) Patient-Derived Xenograft ( HuPrime TM ) Syngeneic Tumor Homograft ( MuPrime TM ) Resources Posters Publications Presentations White Papers On-Demand Webinars Events Quick Facts FactSheets Application Notes Blog Databases Onco Express HuBase OrganoidBase XenoBase MuBase Contact x SYMPOSIUM: Taking Immunotherapies to the Next Level November 7, 2019 - Paris, France Crown Bioscience invites you to attend our Paris symposium focused on Taking Immunotherapies to the Next Level. Join the discussion on how to improve humanised preclinical models, develop the best strategies in optimising syngeneic translational relevance, and how to apply organoids to I/O research and drug development.ON DEMAND WEBINAR: Efficacy and irAE Assessment Of Therapeutic Antibodies With Target Specific Knock-In Models Join Dr Hongjuan Zhang to learn how novel Hu GEMM™ and Hu CELL™ human knock-in models are used to assess human-specific immunotherapies. Explore the latest research applying these platforms to evaluating immune related toxicities, to accelerate immuno-oncology drug discovery programs. NEW WHITE PAPER: Learn When and How to Use Tumor Organoids in Oncology Drug Discovery Learn how to select the right in vitro platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms. ON DEMAND WEBINAR: Shifting the Paradigm of Cancer Treatment: How Can Optical Imaging Help? Join Dr Yinfei Yin to explore the benefits of optical imaging in preclinical oncology research with an emphasis on immunotherapy development. Learn how imaging improves the predictive power of preclinical studies, and allows a more efficient and cost-effective translation into the clinic. Key new imaging models for evaluating novel anticancer agents will also be discussed. Keeping Your Projects Moving During the COVID-19 Pandemic Read the update from Dr. Jean-Pierre Wery, CEO on how we’re balancing our operations while keeping our staff and facilities safe. Find out more about our current global capacity - with all China sites fully operational, and a Proxy SD system for EU/US affected areas ON DEMAND WEBINAR: Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research Join Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies. NEW PUBLICATION: Genomic Analysis of Clinical Chinese ccRCC Samples to Guide Patient Stratification Explore whole-transcriptomic...